|
Last week, we mailed our Facing ALGS Together: An ALGS Mission Brief to homes across our U.S. community. This brief reflects the challenges Alagille Syndrome patients and caregivers are facing today, as understood through ongoing engagement with the community, including surveys, polls, shared experiences, and one-on-one communication with patients, caregivers, and stakeholders.
It is important to acknowledge that this moment looks different than it did even a few years ago. With two FDA approved treatments now available, many patients are now experiencing meaningful relief from cholestatic pruritus, the most debilitating symptom of liver disease associated with ALGS. In the years following these approvals, community feedback has shown a meaningful decrease in patient and caregiver reported suffering in regions where one or both therapies are accessible. Reducing the traumatic and intense burden of pruritus has long been one of the greatest obstacles faced by this community, and progress in this area represents a profound shift for families. We extend our deepest thanks to the teams at Mirum Pharmaceuticals and Ipsen for their continued commitment to supporting individuals and families affected by ALGS worldwide.
As well, the Global ALagille Alliance (GALA) study continues to make a meaningful and lasting impact by advancing knowledge that is shaping our understanding of Alagille Syndrome. Patients, caregivers, clinicians, researchers, and partners across the community have already benefited from these insights, with even more to be learned as this work continues. We extend our deepest thanks to Dr. Binita Kamath, the entire GALA team -past and present, and to all those who have contributed data to the registry. Their commitment and collaboration will continue to inform care, research, and discovery for years to come.
Grounded in this same community input, the Mission Brief names the evolving realities families are navigating today, including daily life beyond symptom management, care coordination across the lifespan, mental health, and long-term outcomes. This work is carried by the patients and caregivers who share their experiences, the donors who make progress possible, and the physicians, scientists, volunteers, partners, and sponsors who stand alongside this community and will help shape the work ahead.
For those who may not have received a mailed copy, or who live outside of the United States, we have included the 2025 ALGSA Mission Brief for you, HERE.
|